U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no Seons are required (Sespond to a collection of information unless it contains a valid OMB control numb

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

COMPL	LETE IF KNOWN
Application Number	10/634,027
Confirmation Number	5050
Filing Date	8/4/2003
First Named Inventor	Artem Gennady Evdokimov
Group Art Unit	
Examiner Name	
Attorney Docket Number	9045M2

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	No.1	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
					
	_				
	-		·		
	 				
				-, -,	
			·		
_					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DO Country Code ³ Number ⁴	CUMENT Kind Code ⁵ (if known)	Publication Date • MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	т°
Ne	. 1	WO 00/65085 A1		11/02/2000	Wemer Risau		<u> </u>
			_				
							
			<u> </u>				
EXAMINER		Noh	eel	417/06	DATE CONSIDERED	-	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Pat nts, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003) Under the Paperwork Reduction Act of 1995, no

DEC 1 8 2003 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 2

СОМРІ	ETE IF KNOWN
Application Number	10/633,742
Confirmation Number	1253
Filing Date	8/4/2003
First Named Inventor	Kevin Gene Peters :
Group Art Unit	
Examiner Name	
Attorney Docket Number	9045M

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journat, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
1.0	2	WANG, Y. et al., "Expressions and Characterization of Wild Type, Truncated, and Mutant Forms of the	
1		Intracellular Region of the Receptor-Like Protein Tyrosine Phosphatase HPTPB*, The J. of biological	
11		Chem., 1992, Vo. 267, No. 23, pp.	
110	3.	WRIGHT, M.B. et al., "Protein-Tyrosine Phosphatases in the Vessel Wall Differential Expression After Acute	
_ NZ		Arterial Injury", Arterioscler Thromb Vasc., 2000, pp. 1189-1198.	
110	4	FACHINGER, G. et al., "Functional Interaction of Vascular Endothelial-Protein-Tyrosine Phosphatase with	-
<u> </u>		the angiopoietin Receptor Tie-2", Oncogene, 1999, Vol. 18, pp. 5948-5953.	
10	5	GAITS, F. et al., "Increase in Receptor-like Protein tyrosine Phosphatase Activity and Expression Level on	
10-0		Density-dependent Growth Arrest of Endothelial Cells", Biochem. J., 1995, Vol 311, pp. 97-103.	٠.
1	6	HARDER, K.W. et al., "Characterization and kinetic analysis of the intracellular domain of human protein	
$\mathcal{N}\mathcal{V}$		tyrosine phosphatase β (HPTPβ) using synthetic phosphopeptides", Biochem J., 1994, Vol. 296, pp. 395-	٠.
100		401.	_
1.0	7	KRUEGER, N.X. et al., "Structural diversity and evolution of human receptor-like protein tyrosine	
M		phosphatases", The EMBRO J., 1990, Vol 9, No. 10, pp. 3241-3252.	
101	8	MARTIN, Y.C., "3D Database Searching in Drug Design", J. of Medicinal Chemistry, 1992, Vol 35, No. 12,	
100		pp. 2145-2154.	
1.01	9	CHANTEAU, S.H. et al., "Synthesis of Anthropomorphic Molecules: The NanoPutians", J. Org. Chem.,	,
100		2003, Vol. 68, pp. 8750-8766.	•
1 10	.10	HOPKINS, S.C. et al., "Inhibitors of Kinesin Activity from Structure-Based Computer Screening",	;
100		Biochemistry, 2000, Vol. 39, pp. 2805-2814.	. ,
We-	11	RAREY, M. et al., "A Fast Flexible Docking Method using an Incremental Construction Algorithm", J. Mol.	
NO		<u>Biol.</u> , 1996, Vol. 261, pp. 470-489.	•
RH L	12	JONES, G. et al., "Development and Validation of a Genetic Algorithm for Flexible Docking", J. Mol. Biol.,	
_/		1997, Vol 267, pp. 727-748.	
110	13	STAHL, M. et al., "Detailed Analysis of Scoring Functions for Virtual Screening", J. Med. Chem., 2001, Vol.	
N	44	44, pp. 1035-1042.	أ
1.0	14	SKOICHET, B.K. et al., "Lead discovery using molecular docking", Chem. Biology, 2002, Vol. 6, pp. 439-	
W(446.	
EVALUATE	i		
EXAMINER		NATED 4/7/66 DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003)